November 18, 2016 - By Nellie Frank · 0 Comments
The stock of TAPIMMUNE INCORPORATED (NASDAQ:TPIV) registered an increase of 41.63% in short interest. TPIV’s total short interest was 31,300 shares in November as published by FINRA. Its up 41.63% from 22,100 shares, reported previously. The stock decreased 6.48% or $0.3 on November 17, hitting $4.33. TapImmune Inc. (NASDAQ:TPIV) has declined 39.86% since April 18, 2016 and is downtrending. It has underperformed by 44.29% the S&P500.
TapImmune Inc. is an immuno-oncology company. The company has a market cap of $35.38 million. The Firm specializes in the development of peptide and gene immunotherapeutics and vaccines for the treatment of cancer. It has a 1.07 P/E ratio. The Firm is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers.
TapImmune Inc., incorporated on October 22, 1991, is an immuno-oncology company. The Firm specializes in the development of peptide and gene immunotherapeutics and vaccines for the treatment of cancer. The Firm is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. The Firm combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells.
More notable recent TapImmune Inc. (NASDAQ:TPIV) news were published by: Jacksonville.com which released: “TapImmune Inc. gets fast track status from FDA for study of its vaccine TPIV …” on February 05, 2016, also Prnewswire.com with their article: “TapImmune Appoints Michael J. Loiacono as Chief Financial Officer” published on August 25, 2016, Prnewswire.com published: “TapImmune Announces Finalization of License Agreement With Mayo Clinic To …” on July 27, 2015. More interesting news about TapImmune Inc. (NASDAQ:TPIV) were released by: Prnewswire.com and their article: “TapImmune Appoints John Bonfiglio as Strategic Advisor” published on February 25, 2015 as well as Seekingalpha.com‘s news article titled: “Does TapImmune Have What It Takes To Succeed?” with publication date: September 18, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank